News & Latest Announcements
Why Streamlined Submissions Don’t Guarantee Global Success
The Harmonization Paradox In the world of global oncology trials, a dangerous illusion has taken hold: the harmonization paradox. With the full implementation of the EU’s…
Read article
BIO 2026: Building Connections That Accelerate Development
BIO International Convention in San Diego was, once again, a truly bright event. For four days, professionals from every corner of the life sciences ecosystem came…
Read article
Accelsiors at Swiss Biotech Day 2026: Embracing a Reinvigorated Industry
Swiss Biotech Day once again proved its standing as a central European hub for innovation, bringing together over 3,500 registrants from 58 countries, 150+ exhibitors, 31…
Read article
Stop Auditing Everything: A 3-Tier Framework for EU AI Compliance
The EU AI Act is daunting. When you read the full text, it feels like you need a massive compliance department just to run a clinical trial. But…
Read article
The AI You Didn’t Buy: Why “Invisible” Algorithms Are the Real Risk in EU Trials
You didn’t commission a custom machine learning model. You didn’t sign a contract for “High-Risk AI.” So, you assume your upcoming EU study is safe from the new EU AI…
Read article
The Safety Gap: Why CAR-T Trials in MS Require the 2024 McDonald Criteria & R3 Governance
Precision & Potency: The Future of Neuro-Immunology Aligning the diagnostic safety of McDonald 2024 with the therapeutic power of CAR-T. The High-Stakes Era of Neuro-Immunology For decades, Multiple Sclerosis…
Read article
The EU-X-CT 6-Point Action Plan: A Blueprint for a New Generation of CROs
After exploring the complex legal, financial, and operational barriers stalling European clinical trials, the natural question is: What’s being done about it? Fortunately, the response is not silence. The EU-X-CT initiative,…
Read article
The Future of CAR-T cell Therapies in Autoimmune Disease: From Concept to Clinical Reality
After six weeks of examining the role of CAR-T cell therapies in autoimmune disease, one thing is clear: this therapy is far more than an incremental…
Read article
CTR, GDPR, and the Cross-Border Void: Navigating the Legal Maze of Pan-European Trials
In the first two parts of our series, we established the business risks and the profound human cost of Europe’s fragmented clinical trial landscape. Now, we…
Read article